Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study

(2015) Sanjoy K Paul et al.   Cardiovascular Diabetology

Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study

(2015) Jil Mamza et al.   Diabetes Therapy

Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study

(2015) Jil Mamza et al.   Diabetes Therapy

Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy

(2014) Angelo Avogaro et al.   Current Diabetes Reports

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes

(2014) D. D'Alessio et al.   DIABETES OBESITY & METABOLISM

Association Between Intensification of Metformin Treatment With Insulin vs Sulfonylureas and Cardiovascular Events and All-Cause Mortality Among Patients With Diabetes

(2014) Christianne L. Roumie et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

(2014) Rury R Holman et al.   LANCET

Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes

(2013) Craig J. Currie et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis

(2013) A. Goto et al.   BMJ-British Medical Journal

Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial

(2012) M. Nauck et al.   DIABETIC MEDICINE

Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials

(2011) Matteo Monami et al.   Experimental Diabetes Research

The Cardiovascular Effects of GLP-1 Receptor Agonists

(2010) Theodore Okerson et al.   Cardiovascular Therapeutics

A1C and Cardiovascular Outcomes in Type 2 Diabetes: A nested case-control study

(2010) D. C. Colayco et al.   DIABETES CARE

Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database

(2010) J. H. Best et al.   DIABETES CARE

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

(2009)   LANCET

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

(2009) Kausik K Ray et al.   LANCET

Incretin-based therapies for type 2 diabetes mellitus

(2009) Julie A. Lovshin et al.   Nature Reviews Endocrinology

Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study

(2008) A.-M. Aas et al.   DIABETES OBESITY & METABOLISM

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE